Systematic review on estimated rates of nephrotoxicity and neurotoxicity in patients treated with polymyxins

Pogue, 2019, Toxicity in patients, Adv Exp Med Biol, 1145, 289, 10.1007/978-3-030-16373-0_17 2017 Oliota, 2019, Nephrotoxicity prevalence in patients treated with polymyxins: a systematic review with meta-analysis of observational studies, Diagn Microbiol Infect Dis, 94, 41, 10.1016/j.diagmicrobio.2018.11.008 Chien, 2020, Is colistin-associated acute kidney injury clinically important in adults? A systematic review and meta-analysis, Int J Antimicrob Agents, 55, 105889, 10.1016/j.ijantimicag.2020.105889 Molina, 2009, New information about the polymyxin/colistin class of antibiotics, Expert Opin Pharmacother, 10, 2811, 10.1517/14656560903334185 Higgins, 2003, Measuring inconsistency in meta-analyses, BMJ, 327, 557, 10.1136/bmj.327.7414.557 Abdellatif, 2016, Efficacy and toxicity of aerosolised colistin in ventilator-associated pneumonia: a prospective, randomised trial, Ann Intensive Care, 6, 26, 10.1186/s13613-016-0127-7 Abdelsalam, 2018, Prospective, comparative clinical study between high-dose colistin monotherapy and colistin–meropenem combination therapy for treatment of hospital-acquired pneumonia and ventilator-associated pneumonia caused by multidrug-resistant Klebsiella pneumoniae, J Glob Antimicrob Resist, 15, 127, 10.1016/j.jgar.2018.07.003 Cisneros, 2019, Colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia (Magic Bullet study): an investigator-driven, open-label, randomized, noninferiority controlled trial, Crit Care, 23, 383, 10.1186/s13054-019-2627-y Durante-Mangoni, 2016, Acute kidney injury during colistin therapy: a prospective study in patients with extensively-drug resistant Acinetobacter baumannii infections, Clin Microbiol Infect, 22, 984, 10.1016/j.cmi.2016.08.004 Durante-Mangoni, 2013, Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial, Clin Infect Dis, 57, 349, 10.1093/cid/cit253 Khalili, 2018, Meropenem/colistin versus meropenem/ampicillin-sulbactam in the treatment of carbapenem-resistant pneumonia, J Comp Eff Res, 7, 901, 10.2217/cer-2018-0037 McKinnell, 2019, Plazomicin for infections caused by carbapenem-resistant Enterobacteriaceae, N Engl J Med, 380, 791, 10.1056/NEJMc1807634 Moradi Moghaddam, 2019, Effect of inhaled colistin on the treatment of ventilator-associated pneumonia due to multi-drug resistant Acinetobacter, Tanaffos, 18, 66 Mosaed, 2018, Interim study: comparison of safety and efficacy of levofloxacin plus colistin regimen with levofloxacin plus high dose ampicillin/sulbactam infusion in treatment of ventilator-associated pneumonia due to multi drug resistant Acinetobacter, Iran J Pharm Res, 17, 206 Motsch, 2020, RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections, Clin Infect Dis, 70, 1799, 10.1093/cid/ciz530 Ordooei Javan, 2017, Nephrotoxicity of high and conventional dosing regimens of colistin: a randomized clinical trial, Iran J Pharm Res, 16, 781 Paul, 2018, Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial, Lancet Infect Dis, 18, 391, 10.1016/S1473-3099(18)30099-9 Rattanaumpawan, 2010, Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria, J Antimicrob Chemother, 65, 2645, 10.1093/jac/dkq360 Sirijatuphat, 2015, Preliminary clinical study of the effect of ascorbic acid on colistin-associated nephrotoxicity, Antimicrob Agents Chemother, 59, 3224, 10.1128/AAC.00280-15 Sirijatuphat, 2014, Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections, Antimicrob Agents Chemother, 58, 5598, 10.1128/AAC.02435-13 Demirdal, 2016, Is inhaled colistin beneficial in ventilator associated pneumonia or nosocomial pneumonia caused by Acinetobacter baumannii?, Ann Clin Microbiol Antimicrob, 15, 11, 10.1186/s12941-016-0123-7 Durakovic, 2011, Efficacy and safety of colistin in the treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in patients with hematologic malignancy: a matched pair analysis, Intern Med, 50, 1009, 10.2169/internalmedicine.50.4270 Gauthier, 2012, Incidence and predictors of nephrotoxicity associated with intravenous colistin in overweight and obese patients, Antimicrob Agents Chemother, 56, 2392, 10.1128/AAC.00028-12 Ipek, 2017, Colistin use in critically ill neonates: a case–control study, Pediatr Neonatol, 58, 490, 10.1016/j.pedneo.2016.10.002 Jean, 2018, Treatment outcomes of patients with non-bacteremic pneumonia caused by extensively drug-resistant Acinetobacter calcoaceticus–Acinetobacter baumannii complex isolates: is there any benefit of adding tigecycline to aerosolized colistimethate sodium?, Medicine (Baltimore), 97, 10.1097/MD.0000000000012278 Kallel, 2007, Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case–control study, Intensive Care Med, 33, 1162, 10.1007/s00134-007-0675-2 Kofteridis, 2010, Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: a matched case–control study, Clin Infect Dis, 51, 1238, 10.1086/657242 Miano, 2018, Attributable risk and time course of colistin-associated acute kidney injury, Clin J Am Soc Nephrol, 13, 542, 10.2215/CJN.06980717 Trifi, 2016, Efficacy and toxicity of high-dose colistin in multidrug-resistant Gram-negative bacilli infections: a comparative study of a matched series, Chemotherapy, 61, 190, 10.1159/000442786 Tumbarello, 2013, Effect of aerosolized colistin as adjunctive treatment on the outcomes of microbiologically documented ventilator-associated pneumonia caused by colistin-only susceptible Gram-negative bacteria, Chest, 144, 1768, 10.1378/chest.13-1018 Turkoglu, 2012, Colistin therapy in critically ill patients with chronic renal failure and its effect on development of renal dysfunction, Int J Antimicrob Agents, 39, 142, 10.1016/j.ijantimicag.2011.10.006 Abboud, 2018, Effect of polymyxin B-containing regimens on renal function for the treatment of carbapenem-resistant Enterobacteriacea mediastinitis, Braz J Infect Dis, 22, 51, 10.1016/j.bjid.2017.10.006 Aggarwal, 2018, Comparison of nephrotoxicity of colistin with polymyxin B administered in currently recommended doses: a prospective study, Ann Clin Microbiol Antimicrob, 17, 15, 10.1186/s12941-018-0262-0 Aitullina, 2019, Colistin use in patients with extreme renal function: from dialysis to augmented clearance, Medicina (Kaunas), 55, 33, 10.3390/medicina55020033 Akajagbor, 2013, Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center, Clin Infect Dis, 57, 1300, 10.1093/cid/cit453 Alan, 2014, Efficacy and safety of intravenous colistin in preterm infants with nosocomial sepsis caused by Acinetobacter baumannii, Am J Perinatol, 31, 1079, 10.1055/s-0034-1371361 Al-Busaidi, 2013, Colistin effectiveness and nephrotoxicity: experience from a tertiary care burns unit in Oman, Eur J Plast Surg, 36, 443, 10.1007/s00238-013-0827-2 Al-Lawama, 2016, Intravenous colistin in the treatment of multidrug-resistant Acinetobacter in neonates, Ann Clin Microbiol Antimicrob, 15, 8, 10.1186/s12941-016-0126-4 Alp, 2017, Efficacy of loading dose of colistin in Acinetobacter baumannii ventilator-associated pneumonia, Infez Med, 25, 311 Alvarado Reyes, 2019, Incidence of acute kidney injury in intermittent versus continuous infusion of polymyxin B in hospitalized patients, Ann Pharmacother, 53, 886, 10.1177/1060028019841898 Assimakopoulos, 2019, Triple combination therapy with high-dose ampicillin/sulbactam, high-dose tigecycline and colistin in the treatment of ventilator-associated pneumonia caused by pan-drug resistant Acinetobacter baumannii: a case series study, Infez Med, 27, 11 Averbuch, 2013, Colistin is relatively safe in hematological malignancies and hematopoietic stem cell transplantation patients, Infection, 41, 991, 10.1007/s15010-013-0471-6 Aydogan, 2018, Colistin nephrotoxicity in the ICU: is it different in the geriatric patients?, Aging Clin Exp Res, 30, 573, 10.1007/s40520-017-0827-3 Aygun, 2019, Can nebulised colistin therapy improve outcomes in critically ill children with multi-drug resistant Gram-negative bacterial pneumonia?, Antibiotics (Basel), 8, 40, 10.3390/antibiotics8020040 Bahar, 2019, 24, 405 Bahlis, 2015, Risk factors for acute kidney injury in patients treated with polymyxin B at a tertiary care medical center, J Bras Nefrol, 37, 446 Balkan, 2014, Colistin nephrotoxicity increases with age, Scand J Infect Dis, 46, 678, 10.3109/00365548.2014.926021 Baradaran, 2018, The impact of acute kidney injury on the risk of mortality and health care utilization among patients treated with polymyxins for severe Gram-negative infections, Open Forum Infect Dis, 5, 10.1093/ofid/ofy191 Bassetti, 2008, Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections, J Antimicrob Chemother, 61, 417, 10.1093/jac/dkm509 Batirel, 2014, Comparison of colistin–carbapenem, colistin–sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections, Eur J Clin Microbiol Infect Dis, 33, 1311, 10.1007/s10096-014-2070-6 Benattar, 2016, The effectiveness and safety of high-dose colistin: prospective cohort study, Clin Infect Dis, 63, 1605, 10.1093/cid/ciw684 Benitez-Cano, 2019, Systemic pharmacokinetics and safety of high doses of nebulized colistimethate sodium in critically ill patients with hospital-acquired and ventilator-associated pneumonia, J Antimicrob Chemother, 74, 3268, 10.1093/jac/dkz356 Betrosian, 2008, Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia, J Infect, 56, 432 Bilgili, 2016, Septic shock is an independent risk factor for colistin-induced severe acute kidney injury: a retrospective cohort study, Int J Clin Exp Med, 9, 14649 Binh, 2015, The efficacy and nephrotoxicity associated with colistin use in an intensive care unit in Vietnam: use of colistin in a population of lower body weight, Int J Infect Dis, 35, 18, 10.1016/j.ijid.2015.03.020 Bosso, 1991, Toxicity of colistin in cystic fibrosis patients, DICP, 25, 1168, 10.1177/106002809102501101 Bozkurt, 2017, Colistin-induced nephrotoxicity and the role of N-acetylcysteine: a retrospective cohort study, J Infect Dev Ctries, 11, 895, 10.3855/jidc.9459 Cagan, 2017, Use of colistin in a neonatal intensive care unit: a cohort study of 65 patients, Med Sci Monit, 23, 548, 10.12659/MSM.898213 Cai, 2016, Clinical efficacy of polymyxin monotherapy versus nonvalidated polymyxin combination therapy versus validated polymyxin combination therapy in extensively drug-resistant Gram-negative bacillus infections, Antimicrob Agents Chemother, 60, 4013, 10.1128/AAC.03064-15 Cara, 2018, Cost-effectiveness analysis of low versus high dose colistin in the treatment of multi-drug resistant pneumonia in Saudi Arabia, Int J Clin Pharm, 40, 1051, 10.1007/s11096-018-0713-x Celebi, 2010, Colistimethate sodium therapy for multidrug-resistant isolates in pediatric patients, Pediatr Int, 52, 410, 10.1111/j.1442-200X.2009.03015.x Cetin, 2016, Colistin efficacy in the treatment of multidrug-resistant and extremely drug-resistant Gram-negative bacterial infections, Turk J Med Sci, 46, 1379, 10.3906/sag-1506-125 Ceylan, 2016, Variables determining the development of colistin-associated renal impairment, Wien Klin Wochenschr, 128, 614, 10.1007/s00508-015-0773-z Chan, 2010, Antimicrobial treatment and clinical outcomes of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia, J Intensive Care Med, 25, 343, 10.1177/0885066610377975 Charra, 2009, Aerosolized colistin in the treatment of multiresistant Pseudomonas aeruginosa nosocomial pneumonia, Signa Vitae, 4, 30, 10.22514/SV42.102009.6 Cheng, 2015, Excess mortality associated with colistin–tigecycline compared with colistin–carbapenem combination therapy for extensively drug-resistant Acinetobacter baumannii bacteremia: a multicenter prospective observational study, Crit Care Med, 43, 1194, 10.1097/CCM.0000000000000933 Cheng, 2010, Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant Gram-negative bacterial infections, Int J Antimicrob Agents, 35, 297, 10.1016/j.ijantimicag.2009.11.016 Cho, 2016, Comparison of clinical characteristics of patients with acute kidney injury after intravenous versus inhaled colistin therapy, Kidney Res Clin Pract, 35, 229, 10.1016/j.krcp.2016.07.005 Choe, 2019, Inhalation with intravenous loading dose of colistin in critically ill patients with pneumonia caused by carbapenem-resistant Gram-negative bacteria, Ther Adv Respir Dis, 13, 10.1177/1753466619885529 Choi, 2014, Inhaled colistin for treatment of pneumonia due to colistin-only–susceptible Acinetobacter baumannii, Yonsei Med J, 55, 118, 10.3349/ymj.2014.55.1.118 Choudhry, 2017, Use of colistin for the treatment of multi drug resistant isolates in neonates, J Pak Med Assoc, 67, 1157 Chuang, 2014, Effectiveness of tigecycline-based versus colistin- based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumannii in a critical setting: a matched cohort analysis, BMC Infect Dis, 14, 102, 10.1186/1471-2334-14-102 Chusri, 2019, Adjunctive therapy of intravenous colistin to intravenous tigecycline for adult patients with non-bacteremic post-surgical intra-abdominal infection due to carbapenem-resistant Acinetobacter baumannii, J Infect Chemother, 25, 681, 10.1016/j.jiac.2019.03.017 Ciftci, 2018, Factors determining nephrotoxicity and mortality in critical care patients receiving colistin, J Infect Dev Ctries, 11, 912, 10.3855/jidc.9443 Collins, 2013, Emergent renal dysfunction with colistin pharmacotherapy, Pharmacotherapy, 33, 812, 10.1002/phar.1271 Conway, 2000, Safety and tolerability of bolus intravenous colistin in acute respiratory exacerbations in adults with cystic fibrosis, Ann Pharmacother, 34, 1238, 10.1345/aph.19370 Crass, 2017, Nephrotoxicity in patients with or without cystic fibrosis treated with polymyxin B compared to colistin, Antimicrob Agents Chemother, 61, 10.1128/AAC.02329-16 Crusio, 2014, Epidemiology and outcome of infections with carbapenem-resistant Gram-negative bacteria treated with polymyxin B–based combination therapy, Scand J Infect Dis, 46, 1, 10.3109/00365548.2013.844350 Dalfino, 2012, High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study, Clin Infect Dis, 54, 1720, 10.1093/cid/cis286 Dalfino, 2015, Colistin-associated acute kidney injury in severely ill patients: a step toward a better renal care? A prospective cohort study, Clin Infect Dis, 61, 1771, 10.1093/cid/civ717 De Leon-Borras, 2019, Polymyxin B for Gram negative multidrug resistant bacteria in a Hispanic population, P R Health Sci J, 38, 15 De Ryke, 2010, Colistin dosing and nephrotoxicity in a large community teaching hospital, Antimicrob Agents Chemother, 54, 4503, 10.1128/AAC.01707-09 Demirtürk, 2016, Evaluation of renal functions in patients treated with colistin, Nobel Medicus, 12, 74 Desai, 2016, Clinical outcomes and safety of colistin in treatment of Gram negative infections: a prospective observational study, Egypt J Crit Care Med, 4, 67, 10.1016/j.ejccm.2016.07.001 Dewan, 2014, Evaluation of risk of nephrotoxicity with high dose, extended-interval colistin administration, Indian J Crit Care Med, 18, 427, 10.4103/0972-5229.136070 Diaz, 2016, Clinical characteristics of carbapenem-resistant Klebsiella pneumoniae infections in ill and colonized children in Colombia, Pediatr Infect Dis J, 35, 237, 10.1097/INF.0000000000000987 Dimitriades, 2014, A retrospective study on the effects of colistin therapy in children with multidrug-resistant Gram-negative bacterial pathogens: impact of HIV status on outcome, Arch Dis Child, 99, 262, 10.1136/archdischild-2013-304540 Doshi, 2011, Nephrotoxicity associated with intravenous colistin in critically ill patients, Pharmacotherapy, 31, 1257, 10.1592/phco.31.12.1257 Dubrovskaya, 2013, Risk factors for treatment failure of polymyxin B monotherapy for carbapenem-resistant Klebsiella pneumoniae infections, Antimicrob Agents Chemother, 57, 5394, 10.1128/AAC.00510-13 Dubrovskaya, 2015, Risk factors for nephrotoxicity onset associated with polymyxin B therapy, J Antimicrob Chemother, 70, 1903, 10.1093/jac/dkv014 Elefritz, 2017, Efficacy and safety of a colistin loading dose, high-dose maintenance regimen in critically ill patients with multidrug-resistant Gram-negative pneumonia, J Intensive Care Med, 32, 487, 10.1177/0885066616646551 Elias, 2010, The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic, J Antimicrob Chemother, 65, 2231, 10.1093/jac/dkq285 Falagas, 2005, Nephrotoxicity of intravenous colistin: a prospective evaluation, Int J Antimicrob Agents, 26, 504, 10.1016/j.ijantimicag.2005.09.004 Falagas, 2005, Toxicity after prolonged (more than four weeks) administration of intravenous colistin, BMC Infect Dis, 5, 1, 10.1186/1471-2334-5-1 Falagas, 2006, Effectiveness and nephrotoxicity of intravenous colistin for treatment of patients with infections due to polymyxin-only-susceptible (POS) Gram-negative bacteria, Eur J Clin Microbiol Infect Dis, 25, 596, 10.1007/s10096-006-0191-2 Falagas, 2010, Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients, Int J Antimicrob Agents, 35, 194, 10.1016/j.ijantimicag.2009.10.005 Falagas, 2009, Intravenous colistimethate (colistin) use in critically ill children without cystic fibrosis, Pediatr Infect Dis J, 28, 123, 10.1097/INF.0b013e31818a5dbd Florescu, 2016, Colistin, an old drug in a new territory, solid organ transplantation, Transplant Proc, 48, 152, 10.1016/j.transproceed.2016.01.011 Forrest, 2017, Pharmacokinetic/toxicodynamic analysis of colistin-associated acute kidney injury in critically ill patients, Antimicrob Agents Chemother, 61, 10.1128/AAC.01367-17 Fotakopoulos, 2016, Outcomes in meningitis/ventriculitis treated with intravenous or intraventricular plus intravenous colistin, Acta Neurochir (Wien), 158, 603, 10.1007/s00701-016-2702-y Ganapathy, 2010, Use of colistin in treating multi-resistant Gram-negative organisms in a specialised burns unit, Burns, 36, 522, 10.1016/j.burns.2009.07.010 Garnacho-Montero, 2013, Clinical efficacy and safety of the combination of colistin plus vancomycin for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii, Chemotherapy, 59, 225, 10.1159/000356004 Garnacho-Montero, 2003, Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP, Clin Infect Dis, 36, 1111, 10.1086/374337 Ghafur, 2019, Retrospective study of nephrotoxicity rate among adult patients receiving colistin compared to beta-lactam antibiotics, Indian J Crit Care Med, 23, 518, 10.5005/jp-journals-10071-23276 Ghafur, 2017, Colistin nephrotoxicity in adults: single centre large series from India, Indian J Crit Care Med, 21, 350, 10.4103/ijccm.IJCCM_140_17 Ghafur, 2016, A retrospective study on colistin nephrotoxicity in pediatric onco-hematology patients, J Pediatr Infect Dis, 10 Gibson, 2016, Influence of colistin dose on global cure in patients with bacteremia due to carbapenem-resistant Gram-negative bacilli, Antimicrob Agents Chemother, 60, 431, 10.1128/AAC.01414-15 Gounden, 2009, Safety and effectiveness of colistin compared with tobramycin for multi-drug resistant Acinetobacter baumannii infections, BMC Infect Dis, 9, 26, 10.1186/1471-2334-9-26 Goverman, 2007, Intravenous colistin for the treatment of multi-drug resistant, Gram-negative infection in the pediatric burn population, J Burn Care Res, 28, 421, 10.1097/BCR.0B013E318053D346 Gregoire, 2014, New colistin population pharmacokinetic data in critically ill patients suggesting an alternative loading dose rationale, Antimicrob Agents Chemother, 58, 7324, 10.1128/AAC.03508-14 Grignolo, 2017, Good tolerability of high dose colistin-based therapy in patients with haematological malignancies, Infection, 45, 505, 10.1007/s15010-017-1010-7 Gul, 2016, Risk factors for colistin-associated acute kidney injury: a multicenter study from Turkey, Jpn J Infect Dis, 69, 109, 10.7883/yoken.JJID.2014.501 Hamada, 2016, Clinical experience with colistin in 9 Japanese patients with infection due to multi-drug resistance pathogens, Jpn J Antibiot, 69, 319 Hartzell, 2009, Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center, Clin Infect Dis, 48, 1724, 10.1086/599225 Hassan, 2018, Incidence and risk factors of nephrotoxicity in patients on colistimethate sodium, Int J Clin Pharm, 40, 444, 10.1007/s11096-018-0607-y Holloway, 2006, Polymyxin B and doxycycline use in patients with multidrug-resistant Acinetobacter baumannii infections in the intensive care unit, Ann Pharmacother, 40, 1939, 10.1345/aph.1H353 Horcajada, 2016, Validation of a colistin plasma concentration breakpoint as a predictor of nephrotoxicity in patients treated with colistin methanesulfonate, Int J Antimicrob Agents, 48, 725, 10.1016/j.ijantimicag.2016.08.020 Hsieh, 2016, Role of aerosolized colistin methanesulfonate therapy for extensively-drug-resistant Acinetobacter baumannii complex pneumonia and airway colonization, J Microbiol Immunol Infect, 49, 523, 10.1016/j.jmii.2014.08.009 Huang, 2010, Intravenous colistin sulfate: a rarely used form of polymyxin E for the treatment of severe multidrug-resistant Gram-negative bacterial infections, Scand J Infect Dis, 42, 260, 10.3109/00365540903490018 Ilhan, 2018, Efficacy and safety of intravenous colistin in very low birth weight preterm infants, Paediatr Drugs, 20, 475, 10.1007/s40272-018-0301-5 Imberti, 2010, Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration, Chest, 138, 1333, 10.1378/chest.10-0463 Inci, 2018, Determination of colistin-related nephrotoxicity and risk factors in intensive care unit, North Clin Istanb, 5, 120 Jajoo, 2011, Intravenous colistin administration in neonates, Pediatr Infect Dis J, 30, 218, 10.1097/INF.0b013e3182064bfe Jang, 2017, Efficacy and toxicity of high-dose nebulized colistin for critically ill surgical patients with ventilator-associated pneumonia caused by multidrug-resistant Acinetobacter baumannii, J Crit Care, 40, 251, 10.1016/j.jcrc.2017.04.004 Jasani, 2016, An audit of colistin use in neonatal sepsis from a tertiary care centre of a resource-limited country, Indian J Med Res, 144, 433, 10.4103/0971-5916.198682 John, 2019, 2262. Ceftazidime–avibactam vs. polymyxin B in the treatment of infections due to carbapenem-resistant Enterobacteriaceae, Open Forum Infect Dis, 6, S774, 10.1093/ofid/ofz360.1940 John, 2018, Severe infusion-related adverse events and renal failure in patients receiving high-dose intravenous polymyxin B, Antimicrob Agents Chemother, 62, 10.1128/AAC.01617-17 Kalin, 2014, Comparison of colistin and colistin/sulbactam for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia, Infection, 42, 37, 10.1007/s15010-013-0495-y Kalin, 2012, Use of high-dose IV and aerosolized colistin for the treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia: do we really need this treatment?, J Infect Chemother, 18, 872, 10.1007/s10156-012-0430-7 Kallel, 2006, Colistin as a salvage therapy for nosocomial infections caused by multidrug-resistant bacteria in the ICU, Int J Antimicrob Agents, 28, 366, 10.1016/j.ijantimicag.2006.07.008 Kapoor, 2013, Intravenous colistin for multidrug-resistant Gram-negative infections in critically ill pediatric patients, Pediatr Crit Care Med, 14, e268, 10.1097/PCC.0b013e31828a740f Kara, 2015, Comparison of the efficacy of colistin monotherapy and colistin combination therapies in the treatment of nosocomial pneumonia and ventilator-associated pneumonia caused by Acinetobacter baumannii, South Afr J Crit Care, 31, 51, 10.7196/SAJCC.2015.v31i2.246 Karaaslan, 2016, Intravenous colistin use for multidrug-resistant Gram-negative infections in pediatric patients, Balkan Med J, 33, 627, 10.5152/balkanmedj.2016.16210 Karabay, 2014, Efficacy of colistin and non-colistin monotherapies in multi-drug resistant Acinetobacter baumannii bacteremia/sepsis, Acta Med Mediter, 30, 1137 Karaiskos, 2015, Colistin population pharmacokinetics after application of a loading dose of 9 MU colistin methanesulfonate in critically ill patients, Antimicrob Agents Chemother, 59, 7240, 10.1128/AAC.00554-15 Karbuz, 2014, The use of colistin in critically ill children in a pediatric intensive care unit, Pediatr Infect Dis J, 33, e19, 10.1097/INF.0000000000000117 Karli, 2013, Colistin use in pediatric intensive care unit for severe nosocomial infections: experience of an university hospital, Ann Clin Microbiol Antimicrob, 12, 32, 10.1186/1476-0711-12-32 Karnik, 2013, Pharmacokinetics of colistin in critically ill patients with multidrug-resistant Gram-negative bacilli infection, Eur J Clin Pharmacol, 69, 1429, 10.1007/s00228-013-1493-9 Katip, 2017, Efficacy and safety of high loading dose of colistin in multidrug-resistant Acinetobacter baumannii: a prospective cohort study, J Intensive Care Med, 34, 996, 10.1177/0885066617725694 Katip, 2017, Clinical outcomes and nephrotoxicity of colistin loading dose for treatment of extensively drug-resistant Acinetobacter baumannii in cancer patients, Infect Drug Resist, 10, 293, 10.2147/IDR.S144314 Katz, 2016, Ten years with colistin: a retrospective case series, Int J Clin Pract, 70, 706, 10.1111/ijcp.12830 Khawcharoenporn, 2014, Colistin-based treatment for extensively drug-resistant Acinetobacter baumannii pneumonia, Int J Antimicrob Agents, 43, 378, 10.1016/j.ijantimicag.2014.01.016 Kim, 2019, Pharmacokinetic characteristics and limited sampling strategies for therapeutic drug monitoring of colistin in patients with multidrug-resistant Gram-negative bacterial infections, Ther Drug Monit, 41, 102, 10.1097/FTD.0000000000000572 Kim, 2009, Clinical characteristics and risk factors of colistin-induced nephrotoxicity, Int J Antimicrob Agents, 34, 434, 10.1016/j.ijantimicag.2009.06.028 Kim, 2016, Comparable efficacy of tigecycline versus colistin therapy for multidrug-resistant and extensively drug-resistant Acinetobacter baumannii pneumonia in critically ill patients, PLoS One, 11 Kim, 2017, Efficacy of nebulized colistin-based therapy without concurrent intravenous colistin for ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii, J Thorac Dis, 9, 555, 10.21037/jtd.2017.02.61 Ko, 2011, Early acute kidney injury is a risk factor that predicts mortality in patients treated with colistin, Nephron Clin Pract, 117, c284, 10.1159/000320746 Koksal, 2016, Evaluation of risk factors for intravenous colistin use-related nephrotoxicity, Oman Med J, 31, 318, 10.5001/omj.2016.62 Koomanachai, 2007, Efficacy and safety of colistin (colistimethate sodium) for therapy of infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii in Siriraj Hospital, Bangkok, Thailand, Int J Infect Dis, 11, 402, 10.1016/j.ijid.2006.09.011 Korkmaz Ekren, 2017, Evaluation of nephrotoxicity and prognosis in patients treated with colistin due to hospital-acquired pneumonia, Tuberk Toraks, 65, 271, 10.5578/tt.59748 Kubin, 2012, Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy, J Infect, 65, 80 Kumar, 2015, Safety and efficacy of intravenous colistin in children, Indian Pediatr, 52, 129, 10.1007/s13312-015-0586-1 Kvitko, 2011, Polymyxin B versus other antimicrobials for the treatment of Pseudomonas aeruginosa bacteraemia, J Antimicrob Chemother, 66, 175, 10.1093/jac/dkq390 Kwa, 2005, Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa, Clin Infect Dis, 41, 754, 10.1086/432583 Kwon, 2010, Predictors of acute kidney injury associated with intravenous colistin treatment, Int J Antimicrob Agents, 35, 473, 10.1016/j.ijantimicag.2009.12.002 Kwon, 2015, Colistin treatment in carbapenem-resistant Acinetobacter baumannii pneumonia patients: incidence of nephrotoxicity and outcomes, Int J Antimicrob Agents, 45, 605, 10.1016/j.ijantimicag.2015.01.011 Kwon, 2014, Efficacy and safety profile comparison of colistin and tigecycline on the extensively drug resistant Acinetobacter baumannii, Biol Pharm Bull, 37, 340, 10.1248/bpb.b13-00109 Lam, 2019, Clinical and microbiological outcomes in obese patients receiving colistin for carbapenem-resistant Gram-negative bloodstream infection, Antimicrob Agents Chemother, 63, 10.1128/AAC.00531-19 Lambiase, 2012, Persistence of carbapenem-resistant Acinetobacter baumannii strains in an Italian intensive care unit during a forty-six month study period, New Microbiol, 35, 199 Larki, 2018, Serum cystatin C for evaluation of acute kidney injury in adults treated with colistin, J Res Pharm Pract, 7, 178 Lee, 2015, Association between colistin dose and development of nephrotoxicity, Crit Care Med, 43, 1187, 10.1097/CCM.0000000000000931 Levin, 1999, Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, Clin Infect Dis, 28, 1008, 10.1086/514732 Lim, 2011, The outcomes of using colistin for treating multidrug resistant Acinetobacter species bloodstream infections, J Korean Med Sci, 26, 325, 10.3346/jkms.2011.26.3.325 Lodise, 2018, A retrospective cohort analysis shows that coadministration of minocycline with colistin in critically ill patients is associated with reduced frequency of acute renal failure, Antimicrob Agents Chemother, 62, 10.1128/AAC.01165-17 Luque, 2017, Urinary concentrations of colistimethate and formed colistin after intravenous administration in patients with multidrug-resistant Gram-negative bacterial infections, Antimicrob Agents Chemother, 61, 10.1128/AAC.02595-16 Makris, 2018, Colistin versus colistin combined with ampicillin-sulbactam for multiresistant Acinetobacter baumannii ventilator-associated pneumonia treatment: an open-label prospective study, Indian J Crit Care Med, 22, 67, 10.4103/ijccm.IJCCM_302_17 Markou, 2003, Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients, Crit Care, 7, R78, 10.1186/cc2358 Markou, 2008, Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, Gram-negative bacilli infections: a prospective, open-label, uncontrolled study, Clin Ther, 30, 143, 10.1016/j.clinthera.2008.01.015 Mastoraki, 2008, Pseudomonas aeruginosa susceptible only to colistin in intensive care unit patients, Surg Infect (Larchmt), 9, 153, 10.1089/sur.2007.004 Mattos, 2019, Polymyxin B clinical outcomes: a prospective study of patients undergoing intravenous treatment, J Clin Pharm Ther, 44, 415, 10.1111/jcpt.12801 Mendes, 2009, Prevalence and risk factors for acute kidney injury associated with parenteral polymyxin B use, Ann Pharmacother, 43, 1948, 10.1345/aph.1M277 Meraz-Munoz, 2018, Chronic kidney disease after acute kidney injury associated with intravenous colistin use in survivors of severe infections: a comparative cohort study, J Crit Care, 44, 244, 10.1016/j.jcrc.2017.11.022 Min, 2018, Risk factors of colistin safety according to administration routes: intravenous and aerosolized colistin, PLoS One, 13, 10.1371/journal.pone.0207588 Moghadam, 2018, Assessment of renal damage in patients with multi-drug resistant strains of pneumonia treated with colistin, Trauma Monthly, 23 Montero, 2009, Effectiveness and safety of colistin for the treatment of multidrug-resistant Pseudomonas aeruginosa infections, Infection, 37, 461, 10.1007/s15010-009-8342-x Mostardeiro, 2013, Nephrotoxicity and efficacy assessment of polymyxin use in 92 transplant patients, Antimicrob Agents Chemother, 57, 1442, 10.1128/AAC.01329-12 Naesens, 2011, A retrospective observational study on the efficacy of colistin by inhalation as compared to parenteral administration for the treatment of nosocomial pneumonia associated with multidrug-resistant Pseudomonas aeruginosa, BMC Infect Dis, 11, 317, 10.1186/1471-2334-11-317 Nandha, 2013, To study the clinical efficacy and nephrotoxicity along with the risk factors for acute kidney injury associated with parenteral polymyxin B, Indian J Crit Care Med, 17, 283, 10.4103/0972-5229.120319 Nazer, 2015, High-dose colistin for microbiologically documented serious respiratory infections associated with carbapenem-resistant Acinetobacter baumannii in critically ill cancer patients: a retrospective cohort study, Infect Dis (Lond), 47, 755, 10.3109/23744235.2015.1055586 Nelson, 2015, Clinical outcomes associated with polymyxin B dose in patients with bloodstream infections due to carbapenem-resistant Gram-negative rods, Antimicrob Agents Chemother, 59, 7000, 10.1128/AAC.00844-15 Ngamprasertchai, 2018, Effectiveness and safety of polymyxin B for the treatment of infections caused by extensively drug-resistant Gram-negative bacteria in Thailand, Infect Drug Resist, 11, 1219, 10.2147/IDR.S169939 Okoduwa, 2018, Nephrotoxicity associated with intravenous polymyxin B once- versus twice-daily dosing regimen, Antimicrob Agents Chemother, 62, 10.1128/AAC.00025-18 Oliveira, 2008, Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp, J Antimicrob Chemother, 61, 1369, 10.1093/jac/dkn128 Omrani, 2015, High dose intravenous colistin methanesulfonate therapy is associated with high rates of nephrotoxicity; a prospective cohort study from Saudi Arabia, Ann Clin Microbiol Antimicrob, 14, 3, 10.1186/s12941-015-0062-8 Ouderkirk, 2003, Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant Gram-negative bacteria, Antimicrob Agents Chemother, 47, 2659, 10.1128/AAC.47.8.2659-2662.2003 Ozkarakas, 2017, Risk factors for colistin-associated nephrotoxicity and mortality in critically ill patients, Turk J Med Sci, 47, 1165, 10.3906/sag-1604-60 Ozsurekci, 2016, Is colistin effective in the treatment of infections caused by multidrug-resistant (MDR) or extremely drug-resistant (XDR) Gram-negative microorganisms in children?, Diagn Microbiol Infect Dis, 85, 233, 10.1016/j.diagmicrobio.2016.02.017 Paksu, 2012, Old agent, new experience: colistin use in the paediatric intensive care unit—a multicentre study, Int J Antimicrob Agents, 40, 140, 10.1016/j.ijantimicag.2012.04.010 Park, 2018, Neutrophil gelatinase–associated lipocalin as a predictor of acute kidney injury in patients during treatment with colistimethate sodium, Infect Chemother, 50, 128, 10.3947/ic.2018.50.2.128 Pastewski, 2008, Parenteral polymyxin B use in patients with multidrug-resistant Gram-negative bacteremia and urinary tract infections: a retrospective case series, Ann Pharmacother, 42, 1177, 10.1345/aph.1K346 Petrosillo, 2014, Clinical experience of colistin–glycopeptide combination in critically ill patients infected with Gram-negative bacteria, Antimicrob Agents Chemother, 58, 851, 10.1128/AAC.00871-13 Peyko, 2020, A comparison of adjusted versus unadjusted doses of polymyxin B based on renal function and incidence of acute kidney injury, J Pharm Pract, 33, 255, 10.1177/0897190018798881 Phe, 2014, In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy, Antimicrob Agents Chemother, 58, 2740, 10.1128/AAC.02476-13 Phe, 2016, Predicting the risk of nephrotoxicity in patients receiving colistimethate sodium: a multicentre, retrospective, cohort study, J Antimicrob Chemother, 71, 3585, 10.1093/jac/dkw329 Pintado, 2008, Intravenous colistin sulphomethate sodium for therapy of infections due to multidrug-resistant Gram-negative bacteria, J Infect, 56, 185 Pogue, 2020, Ceftolozane/tazobactam vs. polymyxin or aminoglycoside-based regimens for the treatment of drug-resistant Pseudomonas aeruginosa, Clin Infect Dis, 72, 304, 10.1093/cid/ciz816 Pogue, 2011, Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system, Clin Infect Dis, 53, 879, 10.1093/cid/cir611 Polat, 2015, Treatment of ventilator-associated pneumonia using intravenous colistin alone or in combination with inhaled colistin in critically ill children, Paediatr Drugs, 17, 323, 10.1007/s40272-015-0133-5 Price, 1970, Effects of large doses of colistin sulphomethate sodium on renal function, Br Med J, 4, 525, 10.1136/bmj.4.5734.525 Quintanilha, 2019, Colistin and polymyxin B for treatment of nosocomial infections in intensive care unit patients: pharmacoeconomic analysis, Int J Clin Pharm, 41, 74, 10.1007/s11096-018-0766-x Ramasubban, 2008, Safety and efficacy of polymyxin B in multidrug resistant Gram-negative severe sepsis and septic shock, Indian J Crit Care Med, 12, 153, 10.4103/0972-5229.45074 Rashizal Sazli, 2017, Colistin-associated nephrotoxicity among patients in intensive care units (ICU) of hospitals in Selangor, Med J Malaysia, 72, 100 Reed, 2001, The pharmacokinetics of colistin in patients with cystic fibrosis, J Clin Pharmacol, 41, 645, 10.1177/00912700122010537 Reina, 2005, Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study, Intensive Care Med, 31, 1058, 10.1007/s00134-005-2691-4 Rigatto, 2016, Multicenter prospective cohort study of renal failure in patients treated with colistin versus polymyxin B, Antimicrob Agents Chemother, 60, 2443, 10.1128/AAC.02634-15 Rios, 2007, Ventilator-associated pneumonia due to colistin susceptible-only microorganisms, Eur Respir J, 30, 307, 10.1183/09031936.00156906 Rocco, 2013, Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study, Crit Care, 17, R174, 10.1186/cc12853 Rodriguez, 1970, Serum electrolyte abnormalities associated with the administration of polymyxin B in febrile leukemic patients, Clin Pharmacol Ther, 11, 106, 10.1002/cpt1970111106 Sabuda, 2008, Utilization of colistin for treatment of multidrug-resistant Pseudomonas aeruginosa, Can J Infect Dis Med Microbiol, 19, 413, 10.1155/2008/743197 Salahuddin, 2017, Fluid overload is an independent risk factor for acute kidney injury in critically Ill patients: results of a cohort study, BMC Nephrol, 18, 45, 10.1186/s12882-017-0460-6 Santamaria, 2009, Nephrotoxicity associated with the use of intravenous colistin, Scand J Infect Dis, 41, 767, 10.1080/00365540903147001 Sekhri, 2013, Parenteral polymyxins: assessing efficacy and safety in critically ill patients with renal dysfunction, Indian J Pharmacol, 45, 608, 10.4103/0253-7613.121373 Shavit, 2013, Urinary neutrophil gelatinase-associated lipocalin for early detection of acute kidney injury in geriatric patients with urinary tract infection treated by colistin, Clin Nephrol, 80, 405, 10.5414/CN107974 Shields, 2017, Defining the incidence and risk factors of colistin-induced acute kidney injury by KDIGO criteria, PLoS One, 12, 10.1371/journal.pone.0173286 Shields, 2017, Ceftazidime–avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia, Antimicrob Agents Chemother, 61, 10.1128/AAC.00883-17 Siddiqui, 2014, Multi-drug resistant Gram negative infections and use of intravenous polymyxin B in critically ill children of developing country: retrospective cohort study, BMC Infect Dis, 14, 626, 10.1186/s12879-014-0626-9 Soares, 2017, Polymyxin-B and vancomycin-associated acute kidney injury in critically ill patients, Pathog Glob Health, 111, 137, 10.1080/20477724.2017.1309338 Sobieszczyk, 2004, Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections, J Antimicrob Chemother, 54, 566, 10.1093/jac/dkh369 Sorli, 2013, Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study, BMC Infect Dis, 13, 380, 10.1186/1471-2334-13-380 Sorli, 2019, Colistin for the treatment of urinary tract infections caused by extremely drug-resistant Pseudomonas aeruginosa: dose is critical, J Infect, 79, 253 Sorli, 2019, Colistin use in patients with chronic kidney disease: are we underdosing patients?, Molecules, 24, 530, 10.3390/molecules24030530 Sorli, 2017, Impact of colistin plasma levels on the clinical outcome of patients with infections caused by extremely drug-resistant Pseudomonas aeruginosa, BMC Infect Dis, 17, 11, 10.1186/s12879-016-2117-7 Spapen, 2011, Renal and neurological side effects of colistin in critically ill patients, Ann Intensive Care, 1, 14, 10.1186/2110-5820-1-14 Tamma, 2013, The use of intravenous colistin among children in the United States: results from a multicenter, case series, Pediatr Infect Dis J, 32, 17, 10.1097/INF.0b013e3182703790 Tanita, 2013, [Parenteral colistin for the treatment of severe infections: a single center experience], Rev Bras Ter Intensiva, 25, 297, 10.5935/0103-507X.20130051 Temocin, 2015, Incidence and risk factors for colistin-associated nephrotoxicity, Jpn J Infect Dis, 68, 318, 10.7883/yoken.JJID.2014.223 Thamlikitkul, 2016, Monitoring of effectiveness and safety of colistin for therapy in resistant Gram-negative bacterial infections in hospitalized patients at Siriraj Hospital, J Med Assoc Thai, 99, 301 Thammathiwat, 2020, Clinical and subclinical acute kidney injury in multidrug-resistant septic patients treated with colistimethate sodium: incidence and clinical outcomes, Nephrology (Carlton), 25, 32, 10.1111/nep.13663 Tigen, 2016, The risk factors of colistin methanesulfonate associated nephrotoxicity, Indian J Crit Care Med, 20, 353, 10.4103/0972-5229.183905 Tigen, 2013, Impact of the initiation time of colistin treatment for Acinetobacter infections, J Infect Chemother, 19, 703, 10.1007/s10156-013-0549-1 Tuon, 2014, Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium, Int J Antimicrob Agents, 43, 349, 10.1016/j.ijantimicag.2013.12.002 Ungthammakhun, 2019, Clinical outcomes of colistin in combination with either 6-g sulbactam or carbapenems for the treatment of extensively drug-resistant Acinetobacter baumannii pneumonia with high MIC to sulbactam: a prospective cohort study, Infect Drug Resist, 12, 2899, 10.2147/IDR.S225518 Vauchel, 2019, Impact of an Acinetobacter baumannii outbreak on kidney events in a burn unit: a targeted machine learning analysis, Am J Infect Control, 47, 435, 10.1016/j.ajic.2018.09.010 Vicari, 2013, Association between colistin dose and microbiologic outcomes in patients with multidrug-resistant Gram-negative bacteremia, Clin Infect Dis, 56, 398, 10.1093/cid/cis909 Vithunes, 2018, Monitoring therapeutic colistin concentrations in critically ill patients admitted to a tertiary care hospital, Drugs Ther Perspective, 34, 534, 10.1007/s40267-018-0548-5 Wilkinson, 2017, Outcome analysis of colistin-treated burn center patients, Burns, 43, 1244, 10.1016/j.burns.2017.03.006 Yilmaz, 2013, Clinical and microbiological efficacy and toxicity of colistin in patients infected with multidrug-resistant Gram-negative pathogens, J Infect Chemother, 19, 57, 10.1007/s10156-012-0451-2 Yilmaz, 2015, Colistin alone or combined with sulbactam or carbapenem against A. baumannii in ventilator-associated pneumonia, J Infect Dev Ctries, 9, 476, 10.3855/jidc.6195 Zaidi, 2014, Efficacy and safety of low-dose colistin in the treatment for infections caused by multidrug-resistant Gram-negative bacteria, J Clin Pharm Ther, 39, 272, 10.1111/jcpt.12138 Zalts, 2016, Treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia: retrospective comparison between intravenous colistin and intravenous ampicillin–sulbactam, Am J Ther, 23, e78, 10.1097/MJT.0b013e3182a32df3 Zavascki, 2008, Pharmacokinetics of intravenous polymyxin B in critically ill patients, Clin Infect Dis, 47, 1298, 10.1086/592577 Zheng, 2020, Colistin for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus–Acinetobacter baumannii complex, J Microbiol Immunol Infect, 53, 854, 10.1016/j.jmii.2019.08.007 Spapen, 2019, Treatment of ventilator-associated pneumonia with high-dose colistin under continuous veno-venous hemofiltration, J Transl Int Med, 7, 100, 10.2478/jtim-2019-0022 Rigatto, 2015, Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: a multicentre prospective cohort study, J Antimicrob Chemother, 70, 1552, 10.1093/jac/dku561 Oliveira, 2009, Polymyxin B and colistimethate are comparable as to efficacy and renal toxicity, Diagn Microbiol Infect Dis, 65, 431, 10.1016/j.diagmicrobio.2009.07.018 Mehta, 2004, Spectrum of acute renal failure in the intensive care unit: the PICARD experience, Kidney Int, 66, 1613, 10.1111/j.1523-1755.2004.00927.x Uchino, 2005, Acute renal failure in critically ill patients: a multinational, multicenter study, JAMA, 294, 813, 10.1001/jama.294.7.813 Hoste, 2015, Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study, Intensive Care Med, 41, 1411, 10.1007/s00134-015-3934-7 Vardakas, 2017, Colistin versus polymyxin B for the treatment of patients with multidrug-resistant Gram-negative infections: a systematic review and meta-analysis, Int J Antimicrob Agents, 49, 233, 10.1016/j.ijantimicag.2016.07.023 Tsuji, 2019, Pharmacotherapy, 39, 10, 10.1002/phar.2209 Pogue, 2017, Clinical considerations for optimal use of the polymyxins: a focus on agent selection and dosing, Clin Microbiol Infect, 23, 229, 10.1016/j.cmi.2017.02.023 Zavascki, 2017, Nephrotoxicity of polymyxins: is there any difference between colistimethate and polymyxin B?, Antimicrob Agents Chemother, 61, 10.1128/AAC.02319-16 Ghlissi, 2013, Evaluation of colistin nephrotoxicity administered at different doses in the rat model, Ren Fail, 35, 1130, 10.3109/0886022X.2013.815091 Nation, 2019, Polymyxin acute kidney injury: dosing and other strategies to reduce toxicity, Antibiotics (Basel), 8, 24, 10.3390/antibiotics8010024 Gai, 2019, Molecular mechanisms of colistin-induced nephrotoxicity, Molecules, 24, 653, 10.3390/molecules24030653 Ordooei Javan, 2015, A review on colistin nephrotoxicity, Eur J Clin Pharmacol, 71, 801, 10.1007/s00228-015-1865-4 Cartin-Ceba, 2012, Risk factors for development of acute kidney injury in critically ill patients: a systematic review and meta-analysis of observational studies, Crit Care Res Pract, 2012, 691013 Nakwan, 2019, The use of colistin for the treatment of multidrug-resistant Gram-negative infections in neonates and infants: a review of the literature, Pediatr Infect Dis J, 38, 1107, 10.1097/INF.0000000000002448 Karageorgos, 2019, Intravenous colistin use for infections due to MDR Gram-negative bacilli in critically ill paediatric patients: a systematic review and meta-analysis, J Antimicrob Chemother, 74, 2497, 10.1093/jac/dkz165 Wang, 2019, Safety and efficacy of colistin alone or in combination in adults with Acinetobacter baumannii infection: a systematic review and meta-analysis, Int J Antimicrob Agents, 53, 383, 10.1016/j.ijantimicag.2018.10.020 Gu, 2014, Colistin for the treatment of ventilator-associated pneumonia caused by multidrug-resistant Gram-negative bacteria: a systematic review and meta-analysis, Int J Antimicrob Agents, 44, 477, 10.1016/j.ijantimicag.2014.07.004 Chen, 2015, Meta-analysis of colistin for the treatment of Acinetobacter baumannii infection, Sci Rep, 5, 17091, 10.1038/srep17091 Gameiro, 2020, Acute kidney injury: from diagnosis to prevention and treatment strategies, J Clin Med, 9, 1704